Molecular analysis for cancer patients at Gustave Roussy
Official title: Gustave Roussy Cancer Profiling
Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT04932525 · Data updated 2026-11-12
This study is testing a way to find specific genetic changes in cancer patients to see if they can get targeted treatments that might work better for them.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 4 sites (Villejuif, Val de Marne and 3 other locations) |
| Status | Recruiting |
| Started | May 10, 2021 |
| Main results expected | May 10, 2033 |
| Study ends | May 10, 2033 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT04932525 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with solid tumors or hematological malignancies.
✕Probably not a fit
Patients who are minors, pregnant, or unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The STING study aims to conduct high throughput molecular analysis, including next generation sequencing and immunological profiling, to identify patients with cancer who have targetable genomic alterations. This multicenter study will explore the mechanisms of sensitivity and resistance to anti-cancer treatments. Patients identified with actionable alterations may be eligible for subsequent clinical trials at Gustave Roussy or other participating centers.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for cancer patients based on their unique genetic profiles.
How similar studies have gone: Other studies utilizing similar high throughput molecular profiling approaches have shown promise in identifying actionable targets in cancer treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Histology: solid malignant tumor or hematological malignancy. 3. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code) 4. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol 2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent 3. Pregnant or breast-feeding women 4. Minors (Age \< 18 years)
Where it's running
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, France Recruiting -
Hôpital Marie-Lannelongue
Le Plessis-Robinson, France Recruiting -
Hôpital Saint-Joseph
Paris, France Not yet recruiting -
Hôpital Foch
Suresnes, France Not yet recruiting
Study contacts
- Principal investigator: Antoine Italiano, MD PhD — Gustave Roussy, Cancer Campus, Grand Paris
- Study coordinator: Antoine Italiano, MD PhD
- Email: antoine.italiano@gustaveroussy.fr
- Phone: +33 (0)1 42 11 42 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating AD1208 for advanced solid tumors
This study is testing a new drug called AD1208 to see if it is safe and tolerable for people with advanced solid tumors.
-
Testing LXP1788 Injection for Advanced Solid Tumors
This study is testing a new injection called LXP1788 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.
-
Genomic profiling for targeted treatment in patients with incurable cancer
This study is testing if using genetic information from tumors can help find better treatment options for people with incurable cancer.
-
Adapting a communication program for Latinx cancer patients
This study is testing a new communication program to help Spanish-speaking cancer patients in the Bronx talk about their health values with their nurses.
-
Testing MPB-1734 in patients with advanced solid tumors
This study is testing a new treatment called MPB-1734 to see if it's safe and effective for people with advanced solid tumors that can't be treated with standard therapies.
-
INV-1120 alone and with pembrolizumab for adults with advanced solid tumors
This Phase 1 study will test whether the experimental drug INV-1120, given alone or with pembrolizumab, is safe and tolerable in adults with advanced solid tumors who have progressed after standard therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.